These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39058442)

  • 1. Periphery Biomarkers Predicting Conversion of Type 2 Diabetes to Pre-Alzheimer-Like Cognitive Decline: A Multicenter Follow-Up Study.
    Liu Y; He B; Du K; Zheng J; Ke D; Mo W; Li Y; Jiang T; Xiong R; Sun F; Zhao S; Wei W; Xu Z; Zhang S; Li S; Wang X; Zhou Q; Ye J; Liang Y; Lin H; Liu Y; Chen L; Zhang H; Zhang Y; Gao Y; Wang JZ
    J Alzheimers Dis; 2024; 100(s1):S115-S129. PubMed ID: 39058442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.
    Park MK; Ahn J; Kim YJ; Lee JW; Lee JC; Hwang SJ; Kim KC
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
    Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
    EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periphery Biomarkers for Objective Diagnosis of Cognitive Decline in Type 2 Diabetes Patients.
    Liu Y; Zhang S; He B; Chen L; Ke D; Zhao S; Zhang Y; Wei W; Xu Z; Xu Z; Yin Y; Mo W; Li Y; Gao Y; Li S; Wang W; Yu H; Wu D; Pi G; Jiang T; Deng M; Xiong R; Lei H; Tian N; He T; Sun F; Zhou Q; Wang X; Ye J; Li M; Hu N; Song G; Peng W; Zheng C; Zhang H; Wang JZ
    Front Cell Dev Biol; 2021; 9():752753. PubMed ID: 34746146
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of glycogen synthase kinase-3β with cognitive impairment in type 2 diabetes patients: a six-year follow-up study.
    Wei W; Xu P; Li L; Mao H; Li N; Wang XQ; Wang L; Xu ZP; Zhao S
    Front Endocrinol (Lausanne); 2024; 15():1386773. PubMed ID: 38660514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between Brain Structure Atrophy and Plasma Amyloid-β and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnestic Mild Cognitive Impairment Explored by Surface-Based Morphometry.
    Li K; Qu H; Ma M; Xia C; Cai M; Han F; Zhang Q; Gu X; Ma Q
    Front Aging Neurosci; 2022; 14():816043. PubMed ID: 35547625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
    Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
    Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
    Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M;
    Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSK-3β activation mediates apolipoprotein E4-associated cognitive impairment in type 2 diabetes mellitus: A multicenter, cross-sectional study.
    Gao Y; Yu H; Liu Y; Xu Z; He B; Liu H; Wang Y; Zhang Y; Liang Y; Yang Y; Zheng J; Wang JZ
    J Diabetes; 2024 Jan; 16(1):e13470. PubMed ID: 37700547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer's continuum.
    Jiang J; Zhuo Z; Wang A; Li W; Jiang S; Duan Y; Ren Q; Zhao M; Wang L; Yang S; Awan MUN; Liu Y; Xu J
    Alzheimers Res Ther; 2024 Jul; 16(1):149. PubMed ID: 38961406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.
    Sagare AP; Deane R; Zetterberg H; Wallin A; Blennow K; Zlokovic BV
    J Alzheimers Dis; 2011; 24(1):25-34. PubMed ID: 21157031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
    Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
    Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects.
    Moradi E; Pepe A; Gaser C; Huttunen H; Tohka J;
    Neuroimage; 2015 Jan; 104():398-412. PubMed ID: 25312773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer's disease in patients with mild cognitive symptoms.
    Arvidsson I; Strandberg O; Palmqvist S; Stomrud E; Cullen N; Janelidze S; Tideman P; Heyden A; Åström K; Hansson O; Mattsson-Carlgren N
    Alzheimers Res Ther; 2024 Mar; 16(1):61. PubMed ID: 38504336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.